Cannabis Bioscience International Holdings Inc. (CBIH) has announced a new patent initiative focused on developing an investigational therapy targeting opioid addiction through endocannabinoid pathways. The company’s research aims to support individuals in recovery by alleviating withdrawal symptoms, modulating neural circuits, and reducing relapse vulnerability to promote greater neurobiological balance. CBIH’s formulation and scientific approach are intended to complement existing treatments during the critical post-detoxification phase. The company stated that this new formulation will be presented to Robert F. Kennedy Jr., Secretary of Health and Human Services, to explore research collaboration and potential next steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 279086) on December 29, 2025, and is solely responsible for the information contained therein.